Trial Profile
EFFICACY AND SAFETY OF ZOFENOPRIL+HYDROCHLOROTHIAZIDE COMBINATION VS. IRBESARTAN+HYDROCHLOROTHIAZIDE COMBINATION IN METABOLIC SYNDROME PATIENTS WITH ESSENTIAL HYPERTENSION NOT CONTROLLED BY PREVIOUS MONOTHERAPY
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jul 2013
Price :
$35
*
At a glance
- Drugs Zofenopril (Primary) ; Hydrochlorothiazide; Irbesartan
- Indications Essential hypertension
- Focus Therapeutic Use
- Acronyms ZAMES
- Sponsors Menarini
- 17 Jun 2013 Results presented at the 23rd European Meeting on Hypertension.
- 06 Apr 2013 Primary endpoint 'Office-blood-pressure' has been met.
- 06 Apr 2013 Primary endpoint 'Diastolic-blood-pressure' has been met.